Skip to main content

Canada Prescriptions for stimulants such as Ritalin, Adderall rising in Ontario, particularly for teen boys: report

Use of prescription stimulants has risen nearly 30 per cent in the past five years, a new study says, but girls are less likely to be taking the drugs than boys, meaning some cases of attention-deficit hyperactivity disorder may be going undiagnosed.

The study, published on Wednesday by the Ontario Drug Policy Research Network, shows prescriptions for stimulants such as Ritalin, Concerta and Adderall are up in all age groups across Ontario. In 2013, 4.7 out of 1,000 people were taking prescription stimulants in Ontario. By 2017, that had risen to six for every 1,000 Ontario residents. Stimulants such as Ritalin and Adderall are approved to treat ADHD and narcolepsy in Canada.

The study found that males are much more likely to receive a prescription for stimulants than females, but the differences are most pronounced among children and teens. For instance, about 5 per cent of boys aged 13 to 18 received a prescription for a stimulant in 2017, the study found, compared with just 2.4 per cent for girls in the same age group.

Story continues below advertisement

The big gap between boys and girls suggests that some cases of ADHD are going undiagnosed, said Doron Almagor, a child and adolescent psychiatrist and chair of the Canadian ADHD Resource Alliance. He said that boys tend to display symptoms of hyperactivity much more frequently than girls and that this sort of behaviour is very quickly noticed by teachers. For girls, ADHD can manifest through symptoms such as an inability to focus and depression, which means the condition is sometimes not recognized for what it is, he said.

“It’s not as visible,” Dr. Almagor said.

Nearly half of the stimulant prescriptions went to people 18 and under, which the researchers said is expected, given that ADHD typically affects young people the most. But the study found the rate of prescriptions going to adults rose significantly in the past five years, which could indicate greater recognition of and treatment for adult ADHD, said Diana Martins, lead author and research program manager at the Ontario Drug Policy Research Network. The drugs may also be increasingly used to treat other conditions such as bipolar disorder or depression, Ms. Martins said.

Researchers attempted to estimate levels of potential inappropriate prescribing of stimulants by measuring early refills of a prior prescription that came from a different doctor and pharmacy. In 2017, less than 1,000 prescriptions were inappropriate – representing 0.12 per cent of all stimulant prescriptions that year. It was a decrease from 1,319 inappropriate prescriptions in 2013.

Peter Selby, a clinician scientist in the addictions division and director of medical education at Toronto’s Centre for Addiction and Mental Health, said the new study raises more questions than it answers. For instance, while the data show more adults are taking prescription stimulants, that doesn’t mean the drugs are being inappropriately prescribed. At the same time, the findings don’t give any insight into how well the drugs are working for those who take them. He said there is a need to better understand how and why people are being prescribed these drugs and whether they are leading to better health outcomes.

“We have no way of knowing people are on the right medication or not,” Dr. Selby said.

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter